Clinical Outcome of Chemotherapy in Metastasis or Recurrent Colorectal Cancer
Article Sidebar
Main Article Content
Abstract
Objective: To study clinical outcome of chemotherapy in metastasis or recurrent colorectal cancer.
Setting: Surin Hospital
Study design: Retrospective analytical research
Sample: All metastasis or recurrent colorectal cancer patients received full course or terminated during July 2007 to February 2008.
Method: The data were retrospectively collected from Out Patient Department card (OPD card) and Admission records to analyze by descriptive statistic.
Result: The study revealed the data of 25 patients. There were 8 and 17 patients received Irinotecan and Oxaliplatin containing, respectively.Age between 18 to 75 years. The highest prevalence baseline characteristic were women (60%), age < 50 years (32%), government official payment (60%), stage III colon cancer (60%), no pre-print order form (64%). Total cost of chemotherapy drug were 7,294,561 baht, seperated by 4,186,582 baht for Irinotecan containing regimen and 3,0107,979 baht for Oxaliplatin containing regimen.
Clinical outcome in term of efficacy; Number of 4 had CEA declined to normal range. Nine patients raise to abnormal range CEA or no change. Twelve patients cannot evaluated.
Clinical outcome in term of safety; The most patients occurred with nausea/vomiting (13 patients), other were mucositis (8 patients), gastrointestinal disturbance such as diarrhea and abdominal pain (10 patients). In term of therapeutic outcome; improvement in 13 patients, worse in 8 and 4 death were found.
Conclusion: Chemotherapy for metastasis or recurrent colorectal cancer in Surin Hospital was reasonable to guideline, but there were not clearing clinical outcome evaluated, for example long-term clinical outcome and quality of life. This study suggested that should be conduct clinical outcome evaluate form to compare with cost analysis because there were important data to make dicision before chemotherapy will start.
Article Details
References
2. สำนักนโยบายและยุทธศาสตร์ สำนักปลัดกระทรวงสาธารณสุข กระทรวงสาธารณสุข. จำนวนและ อัตราตายต่อประชากร 100,000 คน จำแนกตามสาเหตุที่สำคัญ พ.ศ. 2545-2549.
3. ศูนย์รักษาและส่งต่อผู้ป่วยมะเร็งโรงพยาบาล สุรินทร์. รายงานผลการปฏิบัติงานประจำ ปีงบประมาณ 2550.
4. คลังเวชกัณฑ์ยา กลุ่มงานเภสัชกรรม โรงพยาบาลสุรินทร์.รายงานผลการปฏิบัติงาน ประจำปีงบประมาณ พ.ศ. 2550.
5. Delaunoit T, Goldberg RM, Sargent DJ et al. Motarity associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. Cancer 2004;101:2170-2176.
6. Moertel CG, Fleming TR, Macdonald JS, et al. An evaluation of the carcinoem- bryonic antigen (CEA) test for monitor¬ing patients with resected colon cancer. JAMA 1993;270:943-947.
7. Saltz LB, Cox JV, BlankeCet al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
8. Goldberg RM, Sargent D, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
9. Kohne CH, Van Cutsem E, Wils J et al. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gsatrointestinal Group Study 40986. J ClinOncol 2005;23:4856-4865.
10. Disk MB and Frank AS. Advances in Chemotherapy for Colorectal Cancer. Clinical Gastroenterology and Hepatology 2006:4:817.
